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Background: Despite clear emphasis through the Millennium Development Goals, the problem of high maternal
mortality persists especially within low and middle income countries. Various studies report remarkably high
maternal mortality rates in northern Nigeria, where maternal mortality rates exceed 1,000 deaths per 100,000 live
births and eclampsia contributes approximately 40% of maternal deaths. Across Nigeria, diazepam is routinely used
for the management of eclampsia. Prior to February 2008, diazepam was widely used for the management of
eclampsia in Kano State (within northern Nigeria) with case fatality rate being over 20%. While magnesium sulphate
(MgSO4) is recognized as the most effective drug for the management of eclampsia; this study aims to compare
MgSO4 therapy with diazepam therapy in terms of case fatality rates and costs.
Findings: This retrospective study, including 1045 patients with eclampsia and pre-eclampsia during the years 2008
and 2009, reports a drop in case fatality rates from 20.9% (95% CI: 18.7, 23.2) to 2.3% (95% CI: 1.4, 3.2) among
eclampsia patients following the MgSO4 intervention. The study observed no significant difference in the cost of
using MgSO4 therapy compared to diazepam therapy.
Conclusions: The study found a remarkable reduction in case fatality rate due to eclampsia in those who received
MgSO4 therapy with minimal increase in costs when compared to diazepam therapy. Concerted efforts should be
focused on properly introducing MgSO4 into emergency obstetric protocols especially within developing countries
to reduce maternal mortality and also impact on health system performance.
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Introduction
Maternal mortality in the developing world is receiving
increasing attention in recent years [1-4] and signifi-
cantly it is a key emphasis of the Millennium Develop-
ment Goals (MDGs). The World Health Organization
(WHO) reports that hemorrhage/bleeding, infections,
unsafe abortions and eclampsia are common causes of
maternal mortality especially in developing countries [5].
Severe pre-eclampsia and eclampsia-related deaths are
common causes of preventable maternal deaths with* Correspondence: eokereke78@gmail.com
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reproduction in any medium, provided the or99% of these deaths occurring in low and middle income
countries [6,7].
Eclampsia is a major cause of maternal morbidity and
mortality in Nigeria. It was reported to have contributed
to 46.3% of maternal deaths in Kano State [8] and 43%
of maternal deaths in Jigawa State [9]. These figures in-
dicate remarkably high rates of maternal mortality with
high contributions from eclampsia-related maternal
deaths in northern Nigeria.
WHO has recommended the use of magnesium
sulphate (MgSO4) as a safe and low-cost drug to manage
severe pre-eclampsia and eclampsia cases [10]. Studies
have shown that the drug significantly lowers the possi-
bility of seizures in women with severe pre-eclampsia orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eclampsia to eclampsia and generally lowers maternal
mortality [11-14]. In many high income countries, mag-
nesium sulphate has been the drug of choice for over
20 years, but in low and middle income countries diaze-
pam, phenytoin and lytic cocktail are still widely used
[6,15]. The limited use of magnesium sulphate in many
developing countries is attributable to a number of fac-
tors such as lack of or poor dissemination of guidelines
on the use of the drug, lack of training for health work-
ers on how to administer the drug and the perceived
need for monitoring of patients on the drug in intensive
care units. Furthermore because the drug is not very ex-
pensive, there is limited incentive for drug manufac-
turers to produce the drug on a commercial scale [16] as
well as the fact that prepackaged doses of less effective
drugs are more readily available [6].
The objective of the study was to compare MgSO4
therapy with diazepam therapy among eclampsia
patients across ten secondary health facilities in Kano
State within northern Nigeria especially with respect to
impact on case fatality rates and cost implications.
Methods
Study design and study sites
This retrospective study was based on an intervention car-
ried out in Kano State within north-western Nigeria, which
has 44 local government areas (LGAs) and an estimated
total population of 9,401,288 according to the 2006 Niger-
ian national census [17]. Kano State has a demographic
and reproductive health profile that includes a maternal
mortality ratio of over 1,000 deaths per 100,000 live births,
a relatively high total fertility rate of over 7 births per
woman, with 45% of adolescents aged 15 – 19 years hav-
ing already begun childbearing. Furthermore the state like
much of north-western Nigeria is characterized by a low
age at first marriage for women (less than 17 years), infant
mortality rate of over 110 deaths per 1,000 live births and
a modern contraceptive prevalence rate of less than 5%
[18,19]. The selected sites for the MgSO4 intervention
were ten secondary level health facilities serving over half
the total population of Kano State and spread across the
State; these health facilities are managed and maintained
by the Kano state government through the State Health
Management Board. Although MgSO4 has been approved
for marketing and usage in Nigeria, it has not been rou-
tinely used in health facilities for eclamptic cases.
Health workers (doctors and midwives) from the ten
health facilities were trained on how to use MgSO4
through a two day training workshop in January 2008. A
simple protocol for the use of the drug was developed and
then utilized during the training. The participants were
taught how to detect MgSO4 toxicity using clinical meth-
ods and how to administer the antidote (calciumgluconate). After the training, MgSO4was supplied by the
state government with support from Population Council
to the health facilities to replace diazepam as the drug of
choice for the management of severe pre-eclampsia and
eclampsia. The training of the health workers ensured that
all patients with eclampsia across the ten health facilities
received similar treatment with MgSO4. In addition, regu-
lar supportive supervisory visits were conducted to all the
ten facilities to ensure adherence to protocol. Ethical clear-
ance for the intervention was granted by the Kano State
Health Management Board as well as Population Council’s
Ethical Research Review Committee.
Study sample
The study sample consists of a1233 eclampsia patients
from the baseline period (2006 – 2007) who received di-
azepam for the management of eclampsia and 996
eclampsia patients from the intervention period who
received MgSO4 after presenting to the ten secondary
level health facilities selected for the intervention. Simi-
larly there were 49 severe pre-eclampsia patients during
the intervention period who also received MgSO4. This
makes a total of 1045 (severe pre-eclampsia and eclamp-
sia) patients for the intervention period i.e. between Feb-
ruary 2008 and January 2009.
The case fatality rate of patients who received diaze-
pam during the baseline study period was estimated by
analyzing data on case fatality for eclampsia from repre-
sentative facilities across the state. Similarly the case fa-
tality rate was estimated for patients who received
MgSO4 in the ten selected sites during the intervention
period. The case fatality rate for eclampsia is defined as
the number of deaths with eclampsia as the underlying
cause of death per 100 cases of eclampsia that received
MgSO4 in the general hospitals. The relative standard
error (RSE) was used as a measure of an estimated CFR’s
reliability; it was obtained by dividing the standard error
of the estimate (SE) by the estimate itself (CFR)*100.
RSE < 30% was considered reliable.
Data collection and analysis
Data for the study was obtained from the obstetric
records of eclamptic patients. Data collection did not in-
volve collecting data directly from individual patients;
however data was collected from the health records of
eclamptic patients with no unique identifiers. Data ana-
lysis was done using SPSS statistical software version 15.
Comparison was made between diazepam and MgSO4
therapy particularly in terms of case fatality rates and
also cost implications.
bCosts estimation
The estimated cost of using diazepam versus MgSO4 for
managing eclampsia cases was calculated by applying
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the expected number of ampoules required for managing
patients. The cost of managing recurrent convulsions
after a loading dose of MgSO4 during the intervention
period was estimated. The extra cost of replacing diaze-
pam with MgSO4 as the drug of choice for managing
eclampsia per eclampsia patient was also calculated.
Results
Table 1 shows the key characteristics and demographic
profile of the intervention group. Fifty two percent
(52%) of the patients were teenagers and thirty two per-
cent (32%) were young women. Sixty percent (60.4%)
were primigravidae and about four percent (3.7%) were
grand multiparous. Very few women had primary educa-
tion and about seventy four percent (74.1%) were
illiterate. Seventy one percent (71%) were in monogam-
ous relationships and about twenty nine percent (28.8%)
had polygamous relationships. Table 2 shows the caseTable 1 Key characteristics and demographic profile of the pa























Blood pressure on admission
Normal (SBP≤ 139/DBP≤ 89) 0
Hypertensive (SBP≥ 140/DBP≥ 90) 48 (98.0)
Unknown 1 (2.0)fatality rates among eclampsia patients at baseline as
well as during the intervention period. There was a dras-
tic reduction in case fatality rates among eclampsia
patients from 20.9% (95% CI: 18.7, 23.2) to 2.3% (1.4,
3.2) when baseline mortality rates were compared to the
intervention period using MgSO4 therapy. Table 3 high-
lights the number and percentage of patients with recur-
rent convulsions among the eclampsia patients after a
loading dose of MgSO4 was administered during the
intervention period. It shows that more than 90 percent
of patients (92.5%) treated with MgSO4 did not have re-
current fits. When a recurrent convulsion occurred, it
was treated using 2grammes of MgSO4 (almost an am-
poule of MgSO4) administered intravenously. Also about
two percent (2%) of the patients who had clinical toxicity
were detected by loss of deep tendon reflex using a pa-
tellar hammer. All cases of clinical toxicity were treated
by stopping MgSO4 and further treatment with
1gramme of 10% calcium gluconate. Table 4 shows thetients that received MgSO4
=49) Eclampsia patients (n = 996) Total (n = 1045)


















42 (4.2) 42 (4.2)
940 (94.4) 988 (94.5)
14 (1.4) 15 (1.4)
Table 2 Eclampsia case-fatality rates at baseline and










(Eclampsia patients) 1233 258 20.9(18.7, 23.2) 5.5
Intervention period
(Eclampsia patients) 996 23 2.3(1.4, 3.2) 20.9
CFR= Case-Fatality Rate. RSE= Relative standard error.
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MgSO4 compared with diazepam as well as the cost for
treating recurrent convulsions using MgSO4. Expert ad-
vice from clinicians working within the state recom-
mends using about 5 ampoules of diazepam/per day for
2 days which is estimated at N1000 (~6.67 US dollars)
to manage a patient with eclampsia. The Pritchard regi-
men with intramuscular maintenance doses has been
widely recommended for use in low resource settings
[20]. A modified version of the Pritchard regimen i.e.
using about 8 ampoules of MgSO4 within a 24 hour
period, estimated at N1600 (~10.6 US dollars), was
administered to patients in the health facilities during
the intervention period. These figures are calculated
based on the assumption that diazepam costs N100 per
ampoule while MgSO4 costs N200 per ampoule, but
these costs vary widely across Nigeria. In addition, since
just about an ampoule will be required to treat recurrent
convulsions, the cost for treating any recurrent convul-
sions was estimated at N200 (~1.33 US dollars).
Discussion
This study illustrates a reduction in case fatality rates
and the benefits of using MgSO4 for the management of
eclampsia. This finding reiterates the results of the Mag-
pie trials where MgSO4 reduced the relative risk of
eclampsia by half without significant harmful effects on
the mother [12] as well as a review of seven randomized
controlled trials involving 1396 women in which MgSO4
reduced maternal deaths with a risk ratio of 0.59 (95%
CI 0.38 to 0.92) [21]. The results from this study also
reinforce the strong recommendation from the WHO
on the use of MgSO4 over other anticonvulsants for the
treatment of severe preeclampsia and eclampsia [22].Table 3 Recurrent convulsions among the patients with
eclampsia after MgSO4 loading dose




Total 996 (100)At present the estimated cost of managing a convul-
sion and preventing further episodes of eclampsia using
MgSO4 is slightly over 10 US dollars in Nigeria com-
pared with about 7 US dollars if diazepam is utilized. As
illustrated by this study less than 1 in 10 patients given a
loading dose of MgSO4 will likely get recurrent convul-
sions. The extra cost per person per episode for man-
aging eclampsia that will be incurred if MgSO4 replaces
diazepam is estimated to be between 3 to 4 US dollars.
For MgSO4 to be available at cheaper prices, two key
strategies are recommended. First, there is need for the
Nigerian government to ensure proper price control
mechanisms for the drug are put in place while offering
market incentives to encourage local production of
the drug. Second, there maybe need to introduce subsid-
ies for MgSO4 as presently occurs with anti-retroviral
drugs [23].
It is expected over time that the cost of introducing
MgSO4 into health facilities and sustaining its use within
the wider health system should progressively reduce, es-
pecially if a well organized and efficient supply chain
management system for the drug is put in place. Fur-
thermore costs for the procurement of MgSO4, for the
management of eclampsia, when applied at national
levels, should certainly be manageable, if proper econ-
omies of scale are factored into the procurement of the
drug.
The significantly better clinical outcomes highlighted
through the MgSO4 intervention provides firm justifica-
tion for the need to strongly promote the routine use of
MgSO4 in health facilities across Nigeria and not just in
Kano State. There will be a cumulative impact on the
per capita income and gross domestic product (GDP) in
Kano State and across the country if this relatively low-
cost medication is effectively utilized in the fight against
maternal mortality.
With clear clinical and economic benefits associated
with using MgSO4 for eclampsia management, govern-
ments in Nigeria and other low income countries should
work towards producing clear national guidelines on the
use of MgSO4 in concurrence with WHO guidelines.
Ministries of Health at state and national levels could
also create more awareness about the benefits of using
the drug, in collaboration with the World Health
Organization as indicated in a previous publication [23].
Appropriate trainings for health care workers on the use
of the drug should be a priority. Furthermore there
should be necessary policy changes to ensure that the
drug is included in the essential drug list at both state
and national levels.
Following the acknowledgement of the importance of
using MgSO4 for managing eclampsia by WHO,
UNFPA, UNICEF and the World Bank [24] and the suc-
cesses of the MgSO4 intervention in Kano State by
Table 4 Estimated cost per patient of using MgSO4 and Diazepam for eclampsia management
Unit cost/ampoule Ampoules required Total cost/episode
Diazepam N 100 10 N 1000 ($6.67)*
MgSO4 (loading dose) N 200 8 N 1600 ($10.6)*
MgSO4 (Recurrent convulsions) N 200 1 N 200 ($1.33)*
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taken over the supply of the drug to its health facilities.
Preliminary results indicate clear benefits which should
justify the continued use of MgSO4 in the free maternal
and child programme currently run by the Kano State
government. But a key challenge will be to ensure that
there is a steady provision of drugs and supplies to
health facilities as well as for patients in need. Freedman
and others proposed [25] that governments in tackling
the issue of high maternal mortality, should address the
problem from a health systems perspective such that
possible catastrophic costs and poor health services es-
pecially experienced by the poorest populations are
equally addressed. In the final analysis, the use of
MgSO4 for eclampsia management may not entirely be a
“magic bullet” but it should be properly integrated into
the implementation framework for maternal mortality
reduction within the health systems of resource limited
countries, for there to be any significant impact on
health system performance. As suggested by Nyamtema
and others [4], policy makers should ensure that such
key lessons are translated into concrete action plans for
achieving the goals set for maternal and child health in
order to achieve MDGs 4 and 5 across the developing
world.
In conclusion, MgSO4 therapy reduced the case fatality
rate due to eclampsia to a significantly greater extent
than the existing diazepam therapy in ten intervention
centres in Kano State. There is no significant difference
in costs in using both drugs. MgSO4 therapy can be
administered by trained health workers who can
recognize the side-effects and the necessity for stopping
the drug when needed. The continuous supply of the
drug by the government is necessary to replace the
present day less standard diazepam therapy for eclamp-
sia. Prevention of teenage pregnancy and raising the
educational status of women in this region will also help
in the long run to reduce maternal mortality due to
eclampsia.
Endnotes
aAll the 1233 patients who reported during the base-
line/pre-intervention period were recorded and treated
as eclampsia patients and received diazepam.
bTo introduce MgSO4 into the ten selected health fa-
cilities during the intervention period, Population Coun-
cil incurred expenses that included the costs of traininghealth workers, costs associated with monitoring and
evaluation of the MgSO4 intervention as well as cost of
procurement of the drug for use in the selected health
facilities. However the breakdown of these costs was not
included in the costs estimation.
*I US Dollar = 150 Naira.
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